- Home
- REPL vs CYD Comparison
REPL vs CYD Comparison
Compare REPL & CYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- CYD
- Stock Information
- Founded
- REPL 2015
- CYD 1951
- Country
- REPL United States
- CYD Singapore
- Employees
- REPL N/A
- CYD N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- CYD Industrial Machinery/Components
- Sector
- REPL Health Care
- CYD Industrials
- Exchange
- REPL Nasdaq
- CYD Nasdaq
- Market Cap
- REPL 547.0M
- CYD 609.7M
- IPO Year
- REPL 2018
- CYD 1994
- Fundamental
- Price
- REPL $5.71
- CYD $41.00
- Analyst Decision
- REPL Hold
- CYD
- Analyst Count
- REPL 9
- CYD 0
- Target Price
- REPL $7.00
- CYD N/A
- AVG Volume (30 Days)
- REPL 2.1M
- CYD 267.4K
- Earning Date
- REPL 11-11-2025
- CYD 08-08-2025
- Dividend Yield
- REPL N/A
- CYD 1.29%
- EPS Growth
- REPL N/A
- CYD 40.10
- EPS
- REPL N/A
- CYD 1.66
- Revenue
- REPL N/A
- CYD $3,159,401,156.00
- Revenue This Year
- REPL N/A
- CYD $6.43
- Revenue Next Year
- REPL $408.25
- CYD $11.20
- P/E Ratio
- REPL N/A
- CYD $24.31
- Revenue Growth
- REPL N/A
- CYD 17.99
- 52 Week Low
- REPL $2.68
- CYD $8.61
- 52 Week High
- REPL $17.00
- CYD $41.39
- Technical
- Relative Strength Index (RSI)
- REPL 46.92
- CYD 84.09
- Support Level
- REPL $5.60
- CYD $32.71
- Resistance Level
- REPL $6.15
- CYD $33.87
- Average True Range (ATR)
- REPL 0.33
- CYD 1.65
- MACD
- REPL 0.06
- CYD 0.47
- Stochastic Oscillator
- REPL 32.48
- CYD 96.06
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
About CYD China Yuchai International Limited
China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International primarily operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.